• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids.胎粪通过胆固醇和胆汁酸的共同作用损害肺表面活性剂。
Biophys J. 2011 Feb 2;100(3):646-655. doi: 10.1016/j.bpj.2010.12.3715.
2
Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer.暴露于聚合物可逆转血清、胎粪或胆固醇在人工泡沫表面张力计中对肺表面活性剂的抑制作用。
Biophys J. 2012 Oct 3;103(7):1451-9. doi: 10.1016/j.bpj.2012.08.024. Epub 2012 Oct 2.
3
Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.抑制和拮抗天然来源的临床肺表面活性剂——表面活性物质。
PLoS One. 2018 Sep 20;13(9):e0204050. doi: 10.1371/journal.pone.0204050. eCollection 2018.
4
Pulmonary surfactant protein SP-C counteracts the deleterious effects of cholesterol on the activity of surfactant films under physiologically relevant compression-expansion dynamics.肺表面活性物质蛋白 SP-C 可对抗胆固醇在生理相关压缩-扩张动力学下对表面活性剂膜活性的有害影响。
Biophys J. 2009 Nov 18;97(10):2736-45. doi: 10.1016/j.bpj.2009.08.045.
5
In vitro effect of meconium on the physical surface properties and morphology of exogenous pulmonary surfactant.胎粪对外源性肺表面活性物质物理表面性质及形态的体外效应
J Korean Med Sci. 1996 Oct;11(5):429-36. doi: 10.3346/jkms.1996.11.5.429.
6
Palmitoylation of pulmonary surfactant protein SP-C is critical for its functional cooperation with SP-B to sustain compression/expansion dynamics in cholesterol-containing surfactant films.棕榈酰化肺表面活性蛋白 SP-C 对于其与 SP-B 的功能合作至关重要,以维持含有胆固醇的表面活性剂膜的压缩/扩张动力学。
Biophys J. 2010 Nov 17;99(10):3234-43. doi: 10.1016/j.bpj.2010.08.070.
7
Phospholipid packing and hydration in pulmonary surfactant membranes and films as sensed by LAURDAN.通过LAURDAN检测肺表面活性物质膜和薄膜中的磷脂堆积与水合作用。
Biochim Biophys Acta. 2011 Mar;1808(3):696-705. doi: 10.1016/j.bbamem.2010.11.019. Epub 2010 Nov 30.
8
Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro.多粘菌素B/肺表面活性物质混合物增强了对胎粪灭活的抵抗力,并在体外减少革兰氏阴性菌的生长。
Pediatr Res. 2006 Mar;59(3):407-11. doi: 10.1203/01.pdr.0000200806.32822.e6.
9
Inhibition of pulmonary surfactant function by meconium.胎粪对肺表面活性物质功能的抑制作用。
Am J Obstet Gynecol. 1991 Feb;164(2):477-81. doi: 10.1016/s0002-9378(11)80003-7.
10
Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant.
Eur J Pediatr. 2002 Jan;161(1):31-6. doi: 10.1007/s00431-001-0858-8.

引用本文的文献

1
Systematic Analysis of Composition, Interfacial Performance and Effects of Pulmonary Surfactant Preparations on Cellular Uptake and Cytotoxicity of Aerosolized Nanomaterials.肺表面活性剂制剂对雾化纳米材料的组成、界面性能、细胞摄取及细胞毒性影响的系统分析
Small Sci. 2021 Oct 23;1(12):2100067. doi: 10.1002/smsc.202100067. eCollection 2021 Dec.
2
Comparative biophysical study of clinical surfactants using constrained drop surfactometry.采用受限液滴表面张力法对临床用表面活性剂进行比较生物物理研究。
Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L535-L546. doi: 10.1152/ajplung.00058.2024. Epub 2024 Aug 19.
3
Meconium aspiration syndrome: from pathophysiology to treatment.胎粪吸入综合征:从病理生理学到治疗
Ann Med Surg (Lond). 2024 Feb 15;86(4):2023-2031. doi: 10.1097/MS9.0000000000001835. eCollection 2024 Apr.
4
Thermodynamic and Structural Study of Budesonide-Exogenous Lung Surfactant System.布地奈德-外源性肺表面活性剂系统的热力学与结构研究
Int J Mol Sci. 2024 Mar 4;25(5):2990. doi: 10.3390/ijms25052990.
5
Time-Dependent Oxidative Alterations in Plasma and Lung Tissue after Meconium Aspiration in a Rabbit Model.兔模型胎粪吸入后血浆和肺组织的时间依赖性氧化改变
Antioxidants (Basel). 2022 Dec 25;12(1):37. doi: 10.3390/antiox12010037.
6
Meconium Aspiration Syndrome in Animal Models: Inflammatory Process, Apoptosis, and Surfactant Inactivation.动物模型中的胎粪吸入综合征:炎症过程、细胞凋亡和表面活性剂失活
Animals (Basel). 2022 Nov 27;12(23):3310. doi: 10.3390/ani12233310.
7
Techniques to evaluate surfactant activity for a personalized therapy of RDS neonates.评估表面活性剂活性以用于 RDS 新生儿个体化治疗的技术。
Biomed J. 2021 Dec;44(6):671-677. doi: 10.1016/j.bj.2021.11.001. Epub 2021 Nov 7.
8
An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function.一条导致肺功能下降的肺表面活性物质功能抑制的不良结局途径。
Curr Res Toxicol. 2021 May 27;2:225-236. doi: 10.1016/j.crtox.2021.05.005. eCollection 2021.
9
Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations.肺表面活性剂与药物递送:表面活性剂/他克莫司制剂的载体化、释放和靶向。
J Control Release. 2021 Jan 10;329:205-222. doi: 10.1016/j.jconrel.2020.11.042. Epub 2020 Nov 24.
10
Atomic Force Microscopy Imaging of Adsorbed Pulmonary Surfactant Films.吸附的肺表面活性物质膜的原子力显微镜成像
Biophys J. 2020 Aug 18;119(4):756-766. doi: 10.1016/j.bpj.2020.06.033. Epub 2020 Jul 14.

本文引用的文献

1
Lamellar bodies form solid three-dimensional films at the respiratory air-liquid interface.板层小体在呼吸气-液界面形成固态的三维膜。
J Biol Chem. 2010 Sep 3;285(36):28174-82. doi: 10.1074/jbc.M110.106518. Epub 2010 Jun 17.
2
Reductions of phospholipase A(2) inhibition of pulmonary surfactant with hyaluronan.透明质酸对磷脂酶A(2)抑制肺表面活性物质作用的降低。
Exp Lung Res. 2010 Apr;36(3):167-74. doi: 10.3109/01902140903234186.
3
Methyl-beta-cyclodextrin restores the structure and function of pulmonary surfactant films impaired by cholesterol.甲基-β-环糊精可恢复因胆固醇而受损的肺表面活性物质膜的结构和功能。
Biochim Biophys Acta. 2010 May;1798(5):986-94. doi: 10.1016/j.bbamem.2009.12.003. Epub 2009 Dec 16.
4
Pulmonary surfactant protein SP-C counteracts the deleterious effects of cholesterol on the activity of surfactant films under physiologically relevant compression-expansion dynamics.肺表面活性物质蛋白 SP-C 可对抗胆固醇在生理相关压缩-扩张动力学下对表面活性剂膜活性的有害影响。
Biophys J. 2009 Nov 18;97(10):2736-45. doi: 10.1016/j.bpj.2009.08.045.
5
Segregated phases in pulmonary surfactant membranes do not show coexistence of lipid populations with differentiated dynamic properties.肺表面活性物质膜中的分离相并未显示出具有不同动态特性的脂质群体共存。
Biophys J. 2009 Sep 2;97(5):1381-9. doi: 10.1016/j.bpj.2009.06.040.
6
Competitive adsorption: a physical model for lung surfactant inactivation.竞争性吸附:肺表面活性剂失活的物理模型。
Langmuir. 2009 Jul 21;25(14):8131-43. doi: 10.1021/la8039434.
7
An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.新生儿肺表面活性物质概述:遗传学、代谢以及表面活性物质在健康与疾病中的作用
Mol Genet Metab. 2009 Jun;97(2):95-101. doi: 10.1016/j.ymgme.2009.01.015. Epub 2009 Feb 4.
8
The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid.膜胆固醇在决定胆汁酸细胞毒性及熊去氧胆酸细胞保护作用中的角色。
Biochim Biophys Acta. 2009 Feb;1788(2):507-13. doi: 10.1016/j.bbamem.2008.12.008. Epub 2008 Dec 25.
9
High-throughput evaluation of pulmonary surfactant adsorption and surface film formation.
J Lipid Res. 2008 Nov;49(11):2479-88. doi: 10.1194/jlr.D800029-JLR200. Epub 2008 Jul 18.
10
Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation.肺表面活性物质的当前观点——抑制、增强与评估
Biochim Biophys Acta. 2008 Oct;1778(10):1947-77. doi: 10.1016/j.bbamem.2008.03.021. Epub 2008 Apr 8.

胎粪通过胆固醇和胆汁酸的共同作用损害肺表面活性剂。

Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids.

机构信息

Departamento Bioquimica, Facultad Biologia, Universidad Complutense, Madrid, Spain.

Department of Pediatrics, San Francisco General Hospital, University of California, San Francisco, California.

出版信息

Biophys J. 2011 Feb 2;100(3):646-655. doi: 10.1016/j.bpj.2010.12.3715.

DOI:10.1016/j.bpj.2010.12.3715
PMID:21281579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3030210/
Abstract

Mechanisms for meconium-induced inactivation of pulmonary surfactant as part of the meconium aspiration syndrome in newborn infants, to our knowledge, are not clearly understood. Here we have studied the biophysical mechanisms of how meconium affects surface activity of pulmonary surfactant and whether the membrane-perturbing effects of meconium can be mimicked by exposure of surfactant to a mixture of bile acids and cholesterol. Surface activity of pulmonary surfactant complexes purified from animal lungs was analyzed in the absence and in the presence of meconium in standard surface balances and in a captive bubble surfactometer. We have also evaluated accumulation of surfactant at the air-liquid interface by what we believe to be a novel microtiter plate fluorescent assay, and the effect of meconium components on surfactant membrane fluidity using Laurdan fluorescence thermotropic profiles and differential scanning calorimetry thermograms. Rapid interfacial adsorption, low surface tension upon film compression, efficient film replenishment upon expansion, and thermotropic properties of surfactant complexes are all adversely affected by meconium, and, in a similar manner, they are affected by cholesterol/taurocholate mixtures but not by taurocholate alone. We conclude that inhibition of surfactant by meconium can be mimicked by a bile salt-promoted incorporation of excess cholesterol into surfactant complexes. These results highlight the potential pathogenic role of cholesterol-mobilizing agents as a crucial factor resulting in cholesterol induced alterations of structure and dynamics of surfactant membranes and films.

摘要

据我们所知,胎粪引起肺表面活性物质失活的机制,作为新生儿胎粪吸入综合征的一部分,尚未完全清楚。在这里,我们研究了胎粪影响肺表面活性物质表面活性的生物物理机制,以及胎粪暴露于胆盐和胆固醇混合物是否可以模拟表面活性物质的膜破坏作用。在标准表面张力计和俘获泡表面张力仪中,分析了从动物肺中纯化的肺表面活性物质复合物在不存在和存在胎粪的情况下的表面活性。我们还通过我们认为是一种新颖的微量滴定板荧光测定法评估了表面活性剂在气液界面处的积累,以及胎粪成分对表面活性剂膜流动性的影响,使用 Laurdan 荧光热致性曲线和差示扫描量热法热谱。胎粪迅速在界面吸附、薄膜压缩时表面张力低、薄膜扩张时有效补充、表面活性复合物的热致性特性均受到影响,并且以类似的方式受到胆固醇/牛磺胆酸盐混合物的影响,但不受牛磺胆酸盐单独影响。我们得出结论,胎粪对表面活性剂的抑制作用可以通过促进过量胆固醇掺入表面活性剂复合物的胆盐来模拟。这些结果突出了胆固醇动员剂作为导致胆固醇诱导的表面活性剂膜和薄膜结构和动力学改变的关键因素的潜在致病作用。